Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Despina Fotiou, BMBS, MA, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Panagiotis Malandrakis, MD, Foteini Theodorakakou, MD, Ioanna Dialoupi, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Roussou, MD, Evangelos Terpos, MDPhD, Meletios A. Dimopoulos, MD, Efstathios Kastritis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136323

Published: 2020

Journal Articles

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Efstathios Kastritis, MD, Pantelis Roussakis, MSc, Ioannis V Kostopoulos, PhD, Foteini Theodorakakou, MD, Despina Fotiou, BMBS, MA, Nikolaos Kanellias, MD, Ioanna Dialoupi, MD, Magdalini Migkou, Maria Roussou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Asimina Papanikolaou, MD, Anastasia Gatou, MD, Ourania E. Tsitsilonis, MD PhD, Maria Gavriatopoulou, Evangelos Terpos, MDPhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-137353

Published: 2020

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis

Efstathios Kastritis, MD, Ioannis Papassotiriou, PhD, Foteini Theodorakakou, MD, Alexandra Margeli, PhD, Anastasia Barzteliotou, PhD, Eleni Tsiligkeridou, Amalia Andreatou, Despina Fotiou, BMBS, MA, Magdalini Migkou, Nikolaos Kanellias, MD, Ioanna Dialoupi, MD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Maria Gavriatopoulou, Evangelos Terpos, MD PhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-136774

Published: 2020

Journal Articles

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Despina Fotiou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Foteini Theodorakakou, MD, Maria Roussou, MD, Evangelos Terpos, MD PhD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-136248

Published: 2020

Journal Articles

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Eftathios Kastritis, Maria Gavriatopoulou, MD, Maria Roussou, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioanna Dialoupi, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Foteini Theodorakakou, MD, Asimina Papanikolaou, MD, Erasmia Psimenou, MD, Kimon Stamatelopoulos, MD, Efstathios Manios, MD, Maria Irini Tselegkidi, MD, Argyrios Ntalianis, MD, Stavroula Giannouli, MD PhD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1894.

https://doi.org/10.1182/blood-2019-128208

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

NARROW

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Email alerts

ASH Publications

American Society of Hematology

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only